Aerie Pharmaceuticals, Inc. First Quarter 2022 Earnings Call | Aerie Pharmaceuticals, Inc

Skip to main navigation

About Us
Careers
- Working at Aerie
Contact
DISCOVaerie™ Live!
- Overview

Search:

About Us
Products
R&D
Investors
Careers

Aerie has been acquired by Alcon, the global leader in eye care. Learn More

Investors

Aerie has been acquired by Alcon, the global leader in eye care. Learn More

Investor Relations

FAQs
News & Presentations
- News Releases
- Events & Presentations
Stock Information
Reports & Filings
Corporate Governance
Our Leadership
Our Board of Directors
Contact Us
Sign up for email alerts

Aerie Pharmaceuticals, Inc. First Quarter 2022 Earnings Call

May 5, 2022 at 5:00 PM EDT

Listen to webcast

PRODUCTS Overview Rhopressa^® Rocklatan^® DISCOVaerie™ Live! R&D Pipeline Glaucoma Ocular Surface Disease - AR-15512 Retinal Disease - AR-1105 Implant - AR-13503 SR Implant - AR-14034 SR Implant Clinical Trials Research Bibliography Investigator Initiated Research Medical Affairs

INVESTORS FAQs News & Presentations Stock Information Reports & Filings Corporate Governance Our Leadership Our Board of Directors Contact Us

ABOUT US Our Scientific Heritage Aerie At-a-Glance Our Leadership Our Board of Directors Our ESG Commitment CAREERS CONTACT

Corporate Headquarters

4301 Emperor Blvd

Suite 400

Durham, NC 27703

Tel. +1 919-237-5300

Aerie Pharmaceuticals, Inc.
©2023 All Rights Reserved. This site intended for U.S. audiences only.

Terms of Use
Privacy Policy
California Residents

TOP